Vineet Dubey
University of Liverpool, Indian Institute of Technology Roorkee
Research areas: Medicine · Infectious Diseases · Antibiotic Resistance in Bacteria · Antibiotic Use and Resistance · Antibiotics Pharmacokinetics and Efficacy
About
Dr. Vineet Dubey is currently a Postdoctoral Research Associate in the Antimicrobial Pharmacology and Therapeutics Group at the University of Liverpool. His research focuses on investigating the antimicrobial pharmacodynamics of essential medicine list drugs, particularly targeting gram-negative pathogens. Vineet is actively involved in the UKRI-funded Strength in Places and Wellcome Trust projects, where he explores innovative therapeutic strategies to address pressing issues in antimicrobial resistance.
Prior to joining the University of Liverpool, Vineet completed his PhD as a Department of Biotechnology-India Fellow at the Indian Institute of Technology Roorkee, India. His doctoral research centred on developing combination strategies to combat persistence and resistance in Acinetobacter baumannii, a notorious multi-drug resistant pathogen. During his doctoral studies, he actively contributed to and successfully completed DBT-India, Indo-Norway, and SERB-funded projects, advancing his research on combating antimicrobial resistance.
Vineet holds a Bachelor of Technology degree in Biotechnology, bringing a strong foundation in both basic and applied sciences to his current research work. Dr. Vineet Dubey's research is driven by his motivation to unravel the intricate mechanistic pathways of antimicrobial resistance in Gram-negative pathogens, with the goal of developing innovative therapeutic strategies to combat these evolving threats. His work focuses on understanding how these bacteria evade treatment, contributing to the global fight against drug-resistant infections.
Employment
-
University of Liverpool Post Doctoral Research Associate2022 - Present
Education
- 2015 - 2021
Projects & Funding
Projects & funding information is unavailable.
Publications (15)
- Insights into amoxicillin pharmacokinetics using physiology-based pharmacokinetic modelling Save
- Molecular pharmacodynamics of amoxicillin-clavulanic acid for urinary tract infections caused by Escherichia coli Save
- Genotypic-phenotypic discordance for cefiderocol against Enterobacter hormaechei Save
- Molecular pharmacodynamics of amoxicillin-clavulanic acid against Escherichia coli Save
- Drug-resistant Acinetobacter baumannii : mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen Save
- Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation Save
- Susceptibility of OXA-48-like-producing Enterobacterales to flomoxef Save
- Acinetobacter baumannii transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti- Acinetobacter drug development and AMR preparedness Save
- Decoding Bacterial Persistence: Mechanisms and Strategies for Effective Eradication Save
- Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa Save
- Disulfiram enhances meropenem activity against NDM- and IMP-producing carbapenem-resistantAcinetobacter baumanniiinfections Save
- Targeting Superoxide Dismutase Confers Enhanced Reactive Oxygen Species-Mediated Eradication of Polymyxin B-Induced Acinetobacter baumannii Persisters Save
- Biofilms in Antimicrobial Activity and Drug Resistance Save
- Computational Prediction of sRNA in Acinetobacter baumannii Save
- The unusual glycine-rich C terminus of the Acinetobacter baumannii RNA chaperone Hfq plays an important role in bacterial physiology Save